ArticleEJNMMI research2018
Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [
Article in EJNMMI research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Multiple vertebrae improves precision in image-based bone marrow absorbed dose estimation in [EJNMMI physics · 2026Article
- Emerging need of dosimetry in radioligand therapy: a feasible method tested in a large cohort of patients affected by neuroendocrine neoplasms.EJNMMI research · 2026Article
- Radioligand Therapy and Sequencing in Gastroenteropancreatic Neuroendocrine Tumors: A Patient Perspective Review.JCO oncology practice · 2026Review
- A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?EJNMMI physics · 2024Review
- SPECT/CT Image-Derived Absorbed Dose to Red Marrow Correlates with Hematologic Toxicity in Patients Treated with [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Impact of different models based on blood samples and images for bone marrow dosimetry afterEJNMMI physics · 2024Article
- Radiomics and Artificial Intelligence in Radiotheranostics: A Review of Applications for Radioligands Targeting Somatostatin Receptors and Prostate-Specific Membrane Antigens.Diagnostics (Basel, Switzerland) · 2024Review
- A single-institution experience withFrontiers in oncology · 2024Article
- Performance study of a 360° CZT camera for monitoringEJNMMI physics · 2023Article
- Specific Uptake in the Bone Marrow Causes High Absorbed Red Marrow Doses During [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Accuracy of two dosimetry software programs forHeliyon · 2022Article
- Patient-specific dosimetry adapted to variable number of SPECT/CT time-points per cycle forEJNMMI physics · 2022Article
- EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands.European journal of nuclear medicine and molecular imaging · 2022Article
- Practical kidney dosimetry in peptide receptor radionuclide therapy using [EJNMMI physics · 2021Article
- Renal and Red Marrow Dosimetry in Peptide Receptor Radionuclide Therapy: 20 Years of History and Ahead.International journal of molecular sciences · 2021Review
- Deep-Learning Generation of Synthetic Intermediate Projections ImprovesJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- Clinical implementation of PLANET® Dose for dosimetric assessment after [EJNMMI research · 2021Article
- Comparison of commercial dosimetric software platforms in patients treated withMedical physics · 2020Article
- Preclinical Targeted α- and βCancers · 2020Article
- Training Requirements for Theranostics: A Unique Opportunity for Collaboration.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study's aim was to develop our dosimetric methodology using a commercial workstation for the routine evaluation of the organs at risk during peptide receptor radionuclide therapy (PRRT) with
methodsFirst, planar and SPECT sensitivity factors were determined on phantoms. The reconstruction parameters were optimized by SPECT/CT image acquisition using a NEMA IEC phantom containing a 500 ml bottle of
resultsSensitivity factors of 6.11 ± 0.01 and 5.67 ± 0.08 counts/s/MBq were obtained with planar and SPECT/CT acquisitions, respectively. A recovery coefficient of 0.78 was obtained for the modeled L2-L4 red marrow. The mean AD/A admin values were 0.43 ± 0.13 mGy/MBq [0.27-0.91] for kidneys, 0.54 ± 0.58 mGy/MBq [0.12-2.26] for liver, 0.61 ± 0.13 mGy/MBq [0.42-0.89] for spleen, and 0.04 ± 0.02 mGy/MBq [0.01-0.09] for red marrow. The AD/A admin values varied when calculated using the personalized and standard organ mass, particularly for kidneys (p = 1 × 10
conclusionsThe obtained AD/A admin values were in agreement with the literature data. This study shows the technical feasibility of patient dosimetry in clinical practice and the need to obtain patient-specific information.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.